Merck (MRK) Common Equity (2009 - 2026)

Merck (MRK) has reported Common Equity for 18 consecutive years, with $106.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 116.19% year-over-year to $106.1 billion in Q2 2026; TTM through Jun 2026 was $106.1 billion, a 116.19% increase from a year earlier, with the FY2025 full-year figure at $115.6 billion, up 149.3% from the prior year.
• Common Equity was $106.1 billion for Q2 2026 at Merck, up from $45.9 billion in the prior quarter.
• Over five years, Common Equity peaked at $115.6 billion in Q4 2025 and troughed at $37.6 billion in Q4 2023.
• A 5-year average of $55.2 billion and a median of $45.2 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity retreated 18.29% in 2023 and soared 155.05% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $46.1 billion in 2022, then declined by 18.29% to $37.6 billion in 2023, then climbed by 23.22% to $46.4 billion in 2024, then surged by 149.3% to $115.6 billion in 2025, then decreased by 8.25% to $106.1 billion in 2026.
• The last three Common Equity figures came in at $106.1 billion (Q2 2026), $45.9 billion (Q1 2026), and $115.6 billion (Q4 2025), per Business Quant data.